Wegovy injections are FDA approved for adults and children 12 years and older with a body mass index of 30 or more, or patients with additional conditions, such as high cholesterol, hypertension, sleep apnea, type 2 diabetes, heart disease, or other chronic metabolic illnesses, who have body mass index of 27 or more
IL-6 regulation and therapeutic targeting in UC IL-6 involves in the pathogenesis of autoimmune diseases by modulating the balance between Th17 and Treg cells [96]
In these cases, the peptide impurities assessed had (1) equivalent, (2) elevated epitope content, and/or (3) reduced human homology relative to the TPT API
As of an October 2022 report from the Institute for Clinical and Economic Review, a month's supply of Wegovy (semaglutide) ran $1,300